Appropriate end-points for right results in the age of antiangiogenic agents: Future options for phase II trials in patients with recurrent glioblastoma

Alba A. Brandes*, E. Franceschi, Thierry Gorlia, Wolfgang Wick, A. H. Jacobs, B. G. Baumert, Martin J. van den Bent, C.M. Weller, Roger Stupp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)896-903
JournalEuropean Journal of Cancer
Volume48
Issue number6
DOIs
Publication statusPublished - Apr 2012

Keywords

  • Recurrent glioblastoma
  • End-points
  • Overall survival
  • Progression-free survival
  • Overall survival rates

Cite this